System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Enrique Santamaría is an expert in Biochemistry at Universidad Publica de Navarra (Spain). Enrique Santamaría has authored 241 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 2 of them ongoing. SLR score: 740 (community average: 125). How the SLR is computed.

LeadR Profile

Enrique Santamaría Universidad Publica de Navarra Spain
740 ScienceLeadR Reputation 740

Unlock

Register Login
Network Map

Biochemistry

Subspecialties: Neurology - Oncology - Geriatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1998 - 2026
Source: PubMed

University of Navarra

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 241

Citations

Citations: 4 647 1st author: 12 Last author: 58 Unique author: 2

Main journals

Int J Mol Sci 17
Methods Mol Biol 16
Plast Reconstr Surg 11
J Proteomics 10
Ann Oncol 8

Best Journals

Ann Oncol 5
Cancer Cell 1
Signal Transduct Target Ther 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML.
PMID 42742967 — cells, biomedical research, azacitidine, therapeutics		JCI Insight20260
Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines.
PMID 42669843 — cells, pharmaceutical preparations, brain, cell line, brain diseases, proteomics, therapeutics, synucleins, sirtuin 1		Brain Pathol20260
Synergistic chemosensory decline as a multidimensional biomarker of neurodegeneration: A scoping review of the olfactory-gustatory axis in aging.
PMID 42551771 — smell, aging, cognitive dysfunction, biomarkers, taste		Exp Gerontol20260
Unveiling the post translational modification code in Alzheimer's pathogenesis: crosstalk between phosphorylation and acetylation.
PMID 42383928 — proteomics, protein processing, post-translational		Expert Rev Proteomics20260
Mass spectrometry-based proteomics to study gastric carcinogenesis: pathophysiological molecular characterization.
PMID 42380148 — carcinogenesis, proteomics		Sci Rep20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 2

By phase:

N/A 4

By status:

Completed 2
Enrolling by invitation 1
Recruiting 1

By type:

Interventional 3
Observational 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
BIOANCIENT EX Effects of a Physical Exercise Program in Centenarians of the BIOANCIENT Cohort A Randomized Clinical Trial
NCT07723339 — exercise, intelligence, genomics, safety, blood, preventive medicine, aging, cellular senescence, longevity, motor activity, biomarkers, metabolomics, proteomics, precision medicine, frailty, artificial intelligence, healthy aging		N/AEnrolling by invitation2026
BIOANCIENT Cohort of Centenarians in Navarra (1926 1927)
NCT07707297 — intelligence, genomics, blood, preventive medicine, aging, cellular senescence, longevity, biomarkers, metabolomics, proteomics, precision medicine, frailty, artificial intelligence, healthy aging, geroscience		N/ARecruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS